Last reviewed · How we verify

Haemophilus Influenza type b vaccine

GlaxoSmithKline · FDA-approved active Biologic Quality 5/100

Haemophilus Influenza type b vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently FDA-approved.

At a glance

Generic nameHaemophilus Influenza type b vaccine
SponsorGlaxoSmithKline
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Haemophilus Influenza type b vaccine

What is Haemophilus Influenza type b vaccine?

Haemophilus Influenza type b vaccine is a Biologic drug developed by GlaxoSmithKline.

Who makes Haemophilus Influenza type b vaccine?

Haemophilus Influenza type b vaccine is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Haemophilus Influenza type b vaccine in?

Haemophilus Influenza type b vaccine is FDA-approved (marketed).

Related